NCT07140679 2025-09-25
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Emory University
Phase 2 Recruiting
Emory University
Centre Hospitalier Universitaire de Besancon
Hospital Universitario La Fe
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Case Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute